COVID-19 throughout pandemic waves and virus variants: a real-life experience in an Italian hospital

Silvia Dettori Giorgia Brucci Federica Portunato Marta Ponzano Laura Magnasco Michele Mirabella Federica Magnè Emanuele Delfino Elisa Balletto Chiara Sepulcri Antonio Vena Daniele Roberto Giacobbe Cristina Marelli Lorenzo Ball Malgorzata Mikulska Antonio Di Biagio Bianca Bruzzone Alessio Signori Sara Mora Mauro Giacomini Chiara Dentone Matteo Bassetti a Infectious Diseases Unit,IRCCS Ospedale Policlinico San Martino,University of Genoa,Genoa,Italyb Department of Health Sciences (DISSAL),University of Genoa,Genoa,Italyc Section of Biostatistics,Department of Health Sciences,University of Genoa,Genoa,Italyd Hygiene Unit,IRCCS Ospedale Policlinico San Martino,Genoa,Italye Anesthesia and Intensive Care,IRCCS Ospedale Policlinico San Martino,Genoa,Italyf Department of Surgical Sciences and Integrated Diagnostics (DISC),University of Genoa,Genoa,Italyg Department of Informatics,Bioengineering,Robotics and System Engineering (DIBRIS),University of Genoa,Genoa,Italy
DOI: https://doi.org/10.1080/1120009x.2024.2384321
2024-08-21
Journal of Chemotherapy
Abstract:New therapies and vaccines changed the management of COVID-19. The aim of this retrospective study was to describe characteristics, in-hospital mortality and its predictors in patients with moderate/severe COVID-19, considering the 4 different pandemic waves and viral variants' prevalence from February 2020 to January 2022. Among 1135 patients included, 873 (77%) had at least one comorbidity, 177 (16%) were immunocompromised. From waves 1 to 4, patients with severe respiratory failure and ICU admission decreased over time ( p < 0.001), like the length of in-hospital stay ( p < 0.001). Despite a reduction of in-hospital mortality from 19% to 11%, increased risk of death was related to older age and immunocompromising conditions, especially during the 4th wave (HR = 5.07 and HR = 10.86, p < 0.001 respectively) while remdesivir treatment in the 3rd wave (HR = 0.41, p = 0.010) and positive serology (aHR = 0.66, p = 0.027) were protective for survival. These data support the need for tailoring vaccine campaign for future COVID-19 waves.
oncology,pharmacology & pharmacy,infectious diseases
What problem does this paper attempt to address?